Evidence map›Paper›PMID 25068661›Full record

ArticleLaboratory investigation; a journal of technical methods and pathology2014

Detection of somatic mutations in tumors using unaligned clonal sequencing data.

Kate M Sutton, Laura A Crinnion, David Wallace, Sally Harrison, Paul Roberts, Christopher M Watson, Alexander F Markham, David T Bonthron, Philip Quirke, Ian M Carr

Abstract read
PubMed Publisher
In one paragraph

Article in Laboratory investigation; a journal of technical methods and pathology, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Kate M SuttonSection of Pathology and Tumour Biology, Institute of Cancer and Pathology, University of Leeds, St James's University Hospital, Leeds, UK.
Laura A CrinnionYorkshire Regional Genetics Service, St James's University Hospital, Leeds, UK.
David WallaceYorkshire Regional Genetics Service, St James's University Hospital, Leeds, UK.
Sally HarrisonSection of Genetics, Institute of Biomedical and Clinical Sciences, School of Medicine, University of Leeds, St James's University Hospital, Leeds, UK.
Paul RobertsYorkshire Regional Genetics Service, St James's University Hospital, Leeds, UK.
Christopher M WatsonYorkshire Regional Genetics Service, St James's University Hospital, Leeds, UK.ORCID 0000000323711844
Alexander F MarkhamSection of Genetics, Institute of Biomedical and Clinical Sciences, School of Medicine, University of Leeds, St James's University Hospital, Leeds, UK.
David T BonthronSection of Genetics, Institute of Biomedical and Clinical Sciences, School of Medicine, University of Leeds, St James's University Hospital, Leeds, UK.
Philip QuirkeSection of Pathology and Tumour Biology, Institute of Cancer and Pathology, University of Leeds, St James's University Hospital, Leeds, UK.
Ian M CarrSection of Genetics, Institute of Biomedical and Clinical Sciences, School of Medicine, University of Leeds, St James's University Hospital, Leeds, UK.

Funding

Medical Research Council MR/L01629X/1
6 · The paper itself

Abstract

Most cancers arise and evolve as a consequence of somatic mutations. These mutations influence tumor behavior and clinical outcome. Consequently, there is considerable interest in identifying somatic variants within specific genes (such as BRAF, KRAS and EGFR) so that chemotherapy can be tailored to the patient's tumor genotype rather than using a generic treatment based on histological diagnosis alone. Owing to the heterogeneous nature of tumors, a somatic mutation may be present in only a subset of cells, necessitating the use of quantitative techniques to detect rare variants. The highly quantitative nature of next-generation sequencing (NGS), together with the ability to multiplex numerous samples, makes NGS an attractive choice with which to screen for somatic variants. However, the large volumes of sequence data present significant difficulties when applying NGS for the detection of somatic mutations. To alleviate this, we have developed methodologies including a set of data analysis programs, which allow the rapid screening of multiple formalin-fixed, paraffin-embedded samples for the presence of specified somatic variants using unaligned Illumina NGS data.

Indexed as

DNA Mutational AnalysisGenes, erbB-1HumansNeoplasmsProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras ProteinsKRAS protein, humanProto-Oncogene ProteinsProto-Oncogene Proteins B-rafProto-Oncogene Proteins p21(ras)ras Proteins

Identifiers

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.